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Abstract
Background: After focused high dose radiotherapy of brain metastases, differentiation between tumor recurrence
and radiation-induced lesions by conventional MRI is challenging. This study investigates the usefulness of dynamic
O-(2-18F-Fluoroethyl)-L-Tyrosine positron emission tomography (18F-FET PET) in patients with MRI-based suspicion of
tumor recurrence after focused high dose radiotherapy of brain metastases.
Methods: Twenty-two patients with 34 brain metastases (median age 61.9 years) were included. Due to follow-up
scan evaluations after repeated treatment in a subset of patients, a total of 50 lesions with MRI-based suspicion of tumor
recurrence after focused high dose radiotherapy could be evaluated. 18F-FET PET analysis included the assessment
of maximum and mean tumor-to-background ratio (TBRmax and TBRmean) and analysis of time-activity-curves (TAC;
increasing vs. decreasing) including minimal time-to-peak (TTPmin). PET parameters were correlated with histological
findings and radiological-clinical follow-up evaluation.
Results: Tumor recurrence was found in 21/50 cases (15/21 verified by histology, 6/21 by radiological-clinical follow-up)
and radiation-induced changes in 29/50 cases (5/29 verified by histology, 24/29 by radiological-clinical follow-up).
Median clinical-radiological follow-up was 28.3 months (range 4.2–99.1 months). 18F-FET uptake was higher in tumor
recurrence compared to radiation-induced changes (TBRmax 2.9 vs. 2.0, p < 0.001; TBRmean 2.2 vs. 1.7, p < 0.001).
Receiver-operating-characteristic (ROC) curve analysis revealed optimal cut-off values of 2.15 for TBRmax and 1.95
for TBRmean (sensitivity 86 %, specificity 79 %). Increasing TACs and long TTPmin were associated with radiation-induced
changes, decreasing TACs with tumor recurrence (p = 0.01). By combination of TBR and TACs, sensitivity and specificity
could be increased to 93 and 84 %.
Conclusions: In patients with MRI-suspected tumor recurrence after focused high dose radiotherapy, 18F-FET PET has a
high sensitivity and specificity for the differentiation of vital tumor tissue and radiation-induced lesions.
Keywords: Brain metastases, Radiosurgery, 18F-FET PET, Kinetic analysis, Radionecrosis
* Correspondence: Nathalie.Albert@med.uni-muenchen.de
2Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich,
Marchioninistr. 15, 81377 Munich, Germany
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Romagna et al. Radiation Oncology  (2016) 11:139 
DOI 10.1186/s13014-016-0713-8
Background
Focused high dose radiotherapy, such as stereotactic ra-
diosurgery (SRS), is increasingly used for small sized
brain metastases especially in the “oligometastases
situation” [1, 2]. Low-activity iodine-125 brachytherapy
(SBT) is another ablative strategy which has been shown
to be effective especially in recurrent brain metastases
after previously performed radiotherapy [3].
The treatment rationale of both SRS and SBT is to
obtain tumor control through early cytocidal effects as
well as late vascular changes [4]. However, lesions that
undergo such treatment constitute a diagnostic chal-
lenge: in conventional follow-up magnetic resonance im-
aging (MRI) a new ring-shaped contrast enhancement
can arise at the site of the highest delivered dose as indi-
cation of blood-brain barrier (BBB) disruption. These
lesions will either expand or resolve over time [5–7].
Therefore, conventional MRI cannot adequately distin-
guish between tumor recurrence and treatment response
[8]. Recent data suggest that molecular imaging tech-
niques might help to overcome such limitations in intra-
cranial metastases which had previously undergone
focused high dose radiotherapy. Whereas positron
emission tomography (PET) with the widely used 18F-2-
deoxy-2-fluoro-D-glucose (18F-FDG) has low diagnostic
accuracy after SRS, the use of radiolabelled amino acids or
amino acid analogues such as L-methyl-11C-methionine
(11C-MET) and O-(2-18F-Fluoroethyl)-L-Tyrosine (18F-FET)
reaches sensitivity and specificity values in the range of 78
and 100 % rendering especially 18F-FET a highly reliable
tracer in glioma imaging [9–14].
Still, there is only limited data on the diagnostic
impact of 18F-FET PET in intracranial metastases,
especially in case of previous exclusive focused high
dose radiotherapy [12, 15]. For further clarification, we
objected to evaluate if 18F-FET PET can differentiate




Twenty-two patients (median age 61.9 years; 11female/
11 male) with a suspicion of a recurrence of their brain
metastases after previously performed focused high dose
radiotherapy (i.e. SRS and SBT) were included. To rule
out potentially confounding effects of WBRT in addition
to focused high dose radiotherapy on 18F-FET uptake,
we excluded all patients with a history of whole brain
radiotherapy. Thirteen patients suffered from of a single
tumor and 9 patients from multiple metastases (3 lesions
in 3 patients, 2 lesions in 6 patients), which resulted in
34 evaluable lesions.
Static and dynamic 18F-FET PET was performed in all
these patients at the time of the suspected tumor
recurrence. The results of 18F-FET PET investigation
and their classification as either concordant or discord-
ant to the actual tumor status referred either to the cor-
responding tissue diagnosis obtained from PET-guided
biopsy procedures at the time of suspected recurrence
and/or to the results of clinical/radiological follow up
evaluation. In patients with deteriorating neurological
status and/or further lesion growth with steroid resistant
edema after high dose radiotherapy histological evaluation
was aimed whenever possible. Lesions exhibiting un-
changed or regressive MRI findings and a stable/improved
clinical performance over a time period of ≥ 6 months
after the date of the suspected tumor recurrence were
classified as stable disease. When there were new suspi-
cious imaging changes of a lesion and/or clinical deterior-
ation after a ≥ 6 months time interval of stable/regressive
disease after the initial treatment, this suspicion was han-
dled as new case with subsequent new 18F-FET PET inves-
tigation and new follow-up. Each individual metastasis per
patient was evaluated. Criteria for recurrence were based
on the Macdonald criteria [16]: i) the appearance of a new
contrast enhancing area after previously observed com-
plete response or ii) an increase of the enhancing area
(>25 %) after previously observed partial response/stable
disease. Accordingly, an overall number of 16 metastases
(8 patients) were repeatedly analysed at different stages of
the brain disease. Seven out of these 16 tumors underwent
re-treatment with focused high dose radiotherapy (time
interval between first and second treatment: 25 months).
In the remaining nine lesions, 18F-FET PET re-evaluation
was initiated due to an increase in contrast enhancement
and/or steroid-resistant symptomatic edema after a
median latency period of 8.6 months. Of these 9 lesions, 6
were found to be tumor recurrences and 3 were
found to be radiation induced lesions (median follow
up 23.1 months; range 13.6–33.9 months). Thus, a total
number of 50 brain lesions was analysed.
Clinical parameters were determined using patients’
electronic medical records and paper charts. Patients
were evaluated and consented by both an experienced
neurooncologist (FWK) and nuclear medicine physician
(NLA). The study was approved by the institutional
review board. All patients had given written informed
consent.
Radiosurgery, iodine-125 stereotactic brachytherapy and
stereotactic biopsy
Three-dimensional planning for SRS and SBT was rou-
tinely based on computerized tomography (CT) and
MRI (slice thickness <3 mm). The treatment protocol
for SRS was used as described in Schüttrumpf et al. [2].
In brief, the clinical target volume was set equivalent to
the gross tumor volume. Expansion of the gross tumor
volume with 1–2 mm resulted in the planning target
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volume. Radiation dose ranged from 18 to 24 Gy. For
SBT, the definition of the treatment volume and the
treatment planning was done as described in Schwartz
et al. using the BrainLab AG Target software (version
1.19) [17]. The prescribed reference dose calculated to
the outer tumor rim was generally 54.0 Gy. The dose
rate was < 15.0 cGy/h. Prior to SBT, the diagnosis of a
metastasis was confirmed with stereotactic biopsy as
previously described [18]. Whenever the attending
neuropathologist could make the diagnosis of a vital me-
tastasis using smear specimen intraoperatively, SBT was
carried out immediately. In case of intraoperative uncer-
tainty regarding the correct diagnosis, SBT was withheld
and the results of the paraffin embedded analysis was
awaited (all sections were stained with hematoxylin and
eosin). Another CT scan was done at the first postopera-
tive day to demonstrate the correct position of the
implanted seed(s).
18F-FET PET image acquisition and evaluation
Dynamic 18F-FET PET image acquisition was performed
over 40 min after injection of 180 MBq 18F-FET as
described previously at a Siemens ECAT EXACT HR+
PET scanner [6, 19]. Image data were transferred to a
HERMES workstation. 18F-FET PET analysis was
performed for each lesion and included the assessment
of the maximum standardized uptake value (SUV) as
tumor-to-background ratio (TBRmax), the mean tumor-
to-background ratio (TBRmean) and dynamic analysis of
tumoral 18F-FET uptake over time (increasing vs.
decreasing time-activity-curves (TACs)). For the deter-
mination of background activity, a region-of-interest was
drawn in six subsequent slices in the contralateral hemi-
sphere including grey and white matter, added to a
volume-of-interest, and the mean SUV was set as back-
ground acitivity. The TBRmax and TBRmean were calcu-
lated by using the maximum and mean SUV within a
semiautomatically drawn, threshold-based volume-of-
interest (1.8 x background activity). For the dynamic
analysis, a 90 % isocontour threshold region-of-interest
was drawn in the 10–30 min summation images on each
slice of suspicious uptake, and the respective TACs for
the whole dataset were extracted. TACs within a 40 min
time interval after tracer injection were defined as fol-
lows: (i) lesions with homogeneously increasing TACs
with SUV constantly ascending or reaching a peak
followed by a plateau in the subsequent frames was clas-
sified as having increasing TACs and (ii) lesions with
homogeneously or heterogeneously decreasing TACs
with SUV showing an early peak within the first 20 min
time interval followed by a constant descent thereafter were
classified as having decreasing TACs. Early fluctuations in
the TACs within the first short time frames (7 × 10 s
followed by 3 × 30 s) representing noise were excluded
from kinetic analyses. For each slice within the tumor, the
frame with the peak uptake was identified. The starting
time of the frame plus half the frame duration, corre-
sponding to the respective peak value, was set as time to
peak (TTP). The shortest TTP present in at least 2
adjacent slices was defined as minimal TTP (TTPmin) as
described in Jansen et al. [20].
PET findings were evaluated by consensus reading of
two experienced nuclear medicine physicians (NLA and
MU) who were blinded for clinical and histological data
as previously described [21].
MR imaging
Clinical evaluations were combined with MRI at regular
3-month intervals. MRI protocols consisted of T1-
weighted ± gadolinium contrast medium, T2-weighted and
fluid attenuated inversion recovery (FLAIR) sequences.
Slice thickness was 1.0 mm for all MRI sequences and all
sequences were reconstructed in axial, coronal and
sagittal planes.
Statistical analysis
SPSS for Windows (SPSS, Version 21.0, Chicago, IL) was
used for statistical calculations. The evaluated PET
parameters (TBRmax and TBRmean and increasing vs.
decreasing time activity curves) were correlated with
histopathological results when available and with the
clinical follow-up. The comparison between tumor re-
currence and radiation-induced lesion was performed
using the Mann-Whitney-U test for continuously scaled
variables and using the χ2 test for categorical variables.
Continuous parameters were reported as mean ± stand-
ard deviation and range. A two-tailed p-value < 0.05 was
considered significant. Receiver operating characteristic
(ROC) analyses were performed in order to identify the
optimal TBRmax cut-off value for the discrimination be-
tween tumor recurrence and radiation-induced lesion by
choosing the cut-off leading to the highest product of
sensitivity × specificity. Length of local PFS was calcu-
lated from the date of radiosurgery and analysed with
the Kaplan-Meier method.
Results
Patient characteristics and 18F-FET PET results are
summarized in Table 1. Tumor recurrence was found in
21/50 cases (15/21 verified by histology, 6/21 by
radiological-clinical follow-up) and radiation-induced le-
sions in 29/50 cases (5/29 verified by histology, 24/29 by
radiological-clinical follow up data are included in
Table 1). Median clinical and radiological follow up was
28.3 months (range 4.2–99.1 months; individual follow
up data are indicated in Table 1), one patient was lost to
follow-up. Median time from focused high dose radio-
therapy to 18F-FET PET was 13.7 months (range 1.9–
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Table 1 Patient characteristics






1 R parietal NSCLC SRS 1.5 1.4 n.a. n.a. 1.9 Radiation induced
lesion
Follow up 9.4
2 L insular Malignant melanoma SBT 3.4 2.3 Decreasing 12.5 2.1 Tumor Follow up 14.8
3 L insular Malignant melanoma SRS 3.4 2.3 Increasing 35 2.2 Tumor Histology 4.2
4 L parietooccipital NSCLC SBT 2.1 1.9 Decreasing 25 2.4 Tumor Histology 29.9
5 L occipital NSCLC SBT 2.8 2.1 Increasing 35 2.5 Radiation induced
lesion
Follow up 6.7
6 L frontal Malignant melanoma SBT 4.1 2.5 Increasing 35 2.6 Tumor Follow up 4.6
7 L parietal CUP SRS 1.8 1.8 Increasing 35 3 Radiation induced
lesion
Follow up 4.9
8 L pontine Breast cancer SRS 1.5 1.3 n.a. n.a. 4.6 Radiation induced
lesion
Follow up 30.9
9 R temporal Malignant melanoma SRS 2.1 1.9 Increasing 17.5 4.7 Radiation induced
lesion
Follow up 16
10 L frontal Malignant melanoma SRS 2.0 1.9 Decreasing 17.5 4.7 Tumor Histology 16
11 L cerebellar Breast cancer SRS 1.7 1.2 Increasing 35 4.7 Radiation induced
lesion
Follow up 30.9
12 R parietal Malignant melanoma SRS 1.4 1.0 n.a. n.a. 4.8 Radiation induced lesion Follow up 6.8
13 R parietal NSCLC SRS 1.5 1.4 n.a. n.a. 5.3 Tumor Histology 9.4
14 L insular Malignant melanoma SBT 3.2 2.3 Decreasing 17.5 5.4 Radiation induced
lesion
Follow up 14.8
15 R temporal NSCLC SRS 1.5 1.3 n.a. n.a. 6 Radiation induced
lesion
Follow up 13.6
16 L occipital NSCLC SRS 2.8 2.1 Decreasing 12.5 6 Tumor Histology 13.6
17 L temporal Malignant melanoma SRS 2.9 2.1 Increasing 35 6 Radiation induced
lesion
Follow up 33.8
18** R frontal Malignant melanoma SRS 1.4 1.3 Increasing 35 8 Radiation induced
lesion
Follow up 42.5
19 R cerebellar Gastrointestinal
cancer
SRS 2.3 2.0 Decreasing 12.5 8.5 Tumor Histology 18
20 L frontal NSCLC SRS 1.9 1.8 Increasing 35 8.6 Radiation induced
lesion
Histology 35.1
21 R frontal NSCLC SRS 1.6 1.4 Increasing 35 8.7 Radiation induced
lesion
Histology 43.1














Table 1 Patient characteristics (Continued)
23 L frontal Malignant melanoma SRS 2.4 2.0 Decreasing 25 9.1 Tumor Histology 22.2
24 R frontal Gastrointestinal cancer SRS 2.0 1.9 Increasing 25 9.3 Radiation induced
lesion
Histology 17.1
25 R frontal NSCLC SRS 2.0 1.9 Decreasing 25 9.3 Radiation induced
lesion
Histology 23.8
26 R temporal NSCLC SRS 1.5 1.1 n.a. n.a. 9.4 Radiation induced
lesion
Follow up 13.6
27 L insular Malignant melanoma SBT 3.5 2.4 Decreasing 7.5 10.5 Radiation induced
lesion
Follow up 14.8
28 L parietal Malignant melanoma SBT 2.5 2.1 Decreasing 12.5 12.3 Tumor Histology 14.5
29 R temporal Malignant melanoma SRS 1.5 1.2 n.a. n.a. 14 Radiation induced
lesion
Follow up 16
30* L frontal Malignant melanoma SRS 3.5 2.3 Decreasing 7.5 14 Tumor Histology 16
31 L insular Malignant melanoma SBT 3.5 2.4 Decreasing 12.5 14.7 Radiation induced
lesion
Follow up 14.8
32 R occipital Breast cancer SRS 1.8 1.8 Increasing 35 15 Radiation induced
lesion
Follow up 79.2
33 R frontal Breast cancer SRS 2.0 1.9 Increasing 35 15 Radiation induced
lesion
Follow up 79.2
34 L cerebellar Breast cancer SRS 1.8 1.7 Increasing 35 15 Radiation induced
lesion
Follow up 79.2
35 L occipital NSCLC SRS 3.0 2.1 Decreasing 4 15.8 Tumor Histology 25.1
36 L frontal Malignant melanoma SRS 2.1 1.9 Increasing 35 18.2 Radiation induced
lesion
Follow up 24.1
37 R frontal NSCLC SRS 3.0 2.2 Decreasing 12.5 18.6 Tumor Follow up 23.8
38 R frontal Malignant melanoma SRS 3.5 2.2 Increasing 25 19.8 Tumor Follow up 42.5
39 R frontal Malignant melanoma SRS 2.2 2.0 Decreasing 4 19.8 Tumor Follow up 42.5
40 L cerebellar Breast cancer SRS 3.8 2.7 Increasing 35 19.9 Tumor Histology 30.9
41 L pontine Breast cancer SRS 4.3 2.8 Decreasing 25 19.9 Tumor Histology 30,9
42 L frontal Malignant melanoma SRS 2.0 1.9 Decreasing 17.5 20.3 Radiation induced
lesion
Follow up 24.1
43 L frontal Malignant melanoma SRS 2.4 2.0 Decreasing 25 20.8 Tumor Histology 22.2
44 R frontal NSCLC SRS 3.9 2.6 Decreasing 12.5 22.6 Tumor Follow up 23.8
45 R frontal Breast cancer SRS 1.5 1.4 Decreasing 25 22.9 Radiation induced
lesion
Follow up 33












Table 1 Patient characteristics (Continued)
47 R cerebellar NSCLC SRS 2.6 2.0 Decreasing 17.5 23.5 Radiation induced
lesion
Histology 33.6
48 R frontal Malignant melanoma SRS 1.4 1.3 Decreasing 4 28.4 Radiation induced
lesion
Follow up 42.5
49 L parietal NSCLC SRS 1.7 1.5 Increasing 35 42.2 Radiation induced
lesion
Follow up 51.5














90.3 months). Within the first year, 18/29 (62.1 %)
radiation-induced lesions and 10/21 (47.6 %) tumor
relapses occurred. After two years, 27/29 (93.1 %)
radiation-induced lesions and 20/21 (95.2 %) tumor re-
lapses were seen. The rate of tumor relapse and tumor
recurrence within the first 12 or 24 months did not
differ (p = 0.23 and p = 0.62).
Comparison of SUV indices for tumor recurrences vs.
radiation-induced lesions
Fifty lesions were evaluated by 18F-FET PET analysis
(Table 1). Median TBRmax was 2.9 in tumor recurrences
(range 1.5–4.3) and 2.0 in radiation-induced lesions
(range 1.2–3.5; p < 0.001). The median TBRmean was 2.2
in tumor recurrences (range 1.4–2.8) and 1.7 in
radiation-induced lesions (range 1.0–2.4; p < 0.001).
ROC analysis of SUV
Receiver-operating-characteristic (ROC) curve analyses
revealed a TBRmax of 2.15 as optimal cut-off value,
leading to a sensitivity of 86 % and specificity of 79 %
(accuracy 82 %, AUC 0.84, CI 0.73–0.96, p < 0.001). For
the TBRmean, optimal cutoff was 1.95, equally leading to
a sensitivity of 86 % and specificity of 79 % (accuracy
82 %, AUC 0.85, CI 0.74–0.96, p < 0.001).
According to this cut-off value, 18F-FET PET was false
negative in 6 % of cases and false positive in 12 % of cases.
In the false negative cases (n = 3), a median TBRmax of 1.9
(range 1.5–2.1) and a TBRmean of 1.7 (range, 1.4–1.9) were
found, median time from radiotherapy to 18F-FET PET
was 4.1 months (range, 2.4–5.3 months). In the false posi-
tive cases (n = 6), a median TBRmax of 3.1 (range 2.6–3.5)
and a TBRmean of 2.2 (range 2.0–2.4) were seen (median
time from radiotherapy to 18F-FET PET 10.4 months
(range 2.5–23.5 months)).
Evaluation of time activity curve patterns and TTPmin
Analysis of TAC patterns was performed in lesions with
increased 18F-FET uptake (TBRmax ≥ 1.6) and was avail-
able in 42/50 cases. Increasing TACs were seen in 18
cases which were mainly associated with radiation-
induced lesions (14/18 cases, 78 %), while decreasing
TACs were found in 24 cases, of which 16 (67 %) were
tumor recurrences (p = 0.01; two illustrative cases are
given in Fig. 1 and 2). TTPmin was significantly shorter
in tumor recurrences (median 17.5 min) than in
radiation-induced lesions (median 35 min; p = 0.007). Al-
though most of the cases with short TTPmin ≤ 12.5 min
had a tumor recurrence (9/12 cases, 75 %) and most of
cases with late TTPmin of 35 min were radiation-induced
(12/15 cases, 80 %), no reliable cut-off TTPmin could be
defined, as the rate of tumor recurrence and radiation-
induced lesion in lesions with an intermediate TTPmin of
17.5–25 min was 53.3 % vs. 46.7 %. Sensitivity for the
detection of tumor recurrence by the mere qualitative
classification using decreasing TACs as indicator for
tumor recurrence was 80 %, specificity was 63 % (accur-
acy 71 %, AUC 0.72, CI 0.55–0.88, p = 0.02). By adding
dynamic to static PET information, the sensitivity and
specificity for the detection of tumor recurrence could
be increased: for lesions with TBRmax > 2.15 / TBRmean >
1.95 in combination with decreasing TACs a sensitivity
of 93 % and specificity of 83 % were obtained (accuracy
87 %, AUC 0.79, CI 0.66–0.92, p = 0.001).
Static and dynamic PET findings are summarized in
Tables 1 and 2. Nearly identical results could be
achieved for the subgroup of the 34 lesions undergoing a
single 18F-FET PET evaluation (data not shown).
Discussion
Differentiation between radiation-induced lesions and
tumor recurrence after focused high dose radiotherapy
of brain metastases is challenging [8, 15]. In the current
series, nearly 60 % of the metastases exhibiting clinical
and/or radiological signs of tumor progression turned
out to be radiation-induced lesions. In this context, the
place of metabolic imaging and suitable radiotracers still
needs to be defined. 11C-MET, 18F-DOPA and 18F-FET
PET seem to be promising candidates for clinical routine
[10, 11, 22, 23]. The use of 11C-MET however, is limited
by logistic disadvantages (half life of 20 min restricting
the use to sites with an on-site cyclotron [11]. Regarding
Fig. 1 MRI and 18F-FET PET findings in a recurrent brain metastasis after focused high dose radiotherapy (Patient nr. 30). A ring-like contrast
enhancement in the T1-weighted images (a), as well as an extensive edema in the T2-weighted images is seen (b). Both a focal 18F-FET uptake
(TBRmax 3.5, TBRmean 2.3) and decreasing TACs can be observed in static and dynamic PET analysis (c, d)
Romagna et al. Radiation Oncology  (2016) 11:139 Page 7 of 10
18F-DOPA, Lizzaraga and Cicone could recently show
sensitivity and specifity values between 81.3 and 92.3 %
rendering 18F-DOPA a promising radiotracer worthy of
further examination [22, 23]. Using 18F-FET PET,
Galldiks et al. have found sensitivity, specificity and ac-
curacy values of 95, 91 and 93 %, respectively for tumor
detection after radiotherapy of brain metastases in case
of both TBRmean values >1.95 and decreasing TACs [10].
Our results are in line with this study. This is especially
true for the congruent TBRmean cut-off value of >1.95,
rendering this parameter clinically valuable due to its
applicability in different sites. Interestingly, the TBRmean
threshold was identical despite differences in pretreat-
ment between the two studies (exclusive focused high
dose radiotherapy in our study versus mixed pretreat-
ment with whole brain radiotherapy in the study by
Galldiks). This might indicate that focused high dose
radiotherapy itself determines the threshold values in
PET imaging and that additional pretreatment with
whole brain radiotherapy might not have a profound
impact on TBR values.
Of note, compared to the above-mentioned study by
Galldiks and colleagues, a lower cut-off value for TBRmax
was found in our series (2.15 vs. 2.55). This might be
explained by differing image reconstruction protocols,
i.e. filtered-back projection in our study versus iterative
reconstruction in the above-mentioned study. Lately,
iterative reconstruction has been reported to be associ-
ated with higher TBRmax values in gliomas compared to
filtered-back projection [24]. Therefore, the reported
TBRmax cutoff values can possibly only be used with the
same image reconstruction parameters, while the
TBRmean cut-off value seems to be more stable.
Our findings uncover diagnostic pitfalls after focused
high dose radiotherapy of brain metastases. Our false
positive cases (6/50) had markedly high TBR values
(median TBRmax 3.1, range 2.6–3.5; median TBRmean 2.2,
range 2.0–2.4). Pretreatment was SRS in 4 cases and
SBT in 2 cases and latency between 18F-FET PET
and treatment ranged from 2.5–23.5 months (median
10.4 months). With regard to these parameters, the false
positive cases did not differ from the correctly diagnosed
tumor recurrences so that no explanation can be found
for the apparently unspecific high 18F-FET uptake in these
radiation-induced lesions. In our false negatives cases
(3/50), the lesion size was remarkably small (median MR
volume 0.6 ml, range 0.2–1.1 ml). In these cases, both the
partial volume effect and the resolution have possibly
contributed to the low TBRmax and TBRmean values which
were below the cutoff and therefore did not identify these
small lesions as tumor tissue. In summary, these false
positive/false negative result might anticipate a “lesional
instability” leading to following clinical implications for
the management of patients with brain metastases after
focused high dose radiotherapy: i) suspicious lesions with
high TBR values exceeding the cutoff should be histologi-
cally evaluated to verify tumor recurrence and to avoid
overtreatment; ii) suspicious lesions with low TBR values
below the cutoff do not need to be evaluated histologically
and can be observed, however, iii) when being of small
volume, should undergo closer follow-up as partial vol-
ume effects might hamper the PET evaluation. Further-
more, our observed rate of radiation-induced lesions as
function of time implies that the risk for a radionecrosis is
highest within the first two years after high-dose radio-
therapy. Therefore, the time interval between radiotherapy
Table 2 Results of diagnostic performance
Identification of recurrent tumor TBRmax > 2.15 TBRmean > 1.95 Decreasing TACs Decreasing TACs in combination
with TBRmax > 2.15/TBRmean > 1.95
Sensitivity 86 % 86 % 85 % 93 %
Specificity 79 % 79 % 60 % 84 %
Accuracy 82 % 82 % 74 % 88 %
Fig. 2 MRI and 18F-FET PET findings in a radiation-induced lesion after focused high dose radiotherapy (Patient nr. 18). A ring-like contrast enhancement
in the T1-weighted images (a), as well as an extensive edema in the T2-weighted images is seen (b). Both a marginal focal 18F-FET uptake (TBRmax 1.4,
TBRmean 1.3) and increasing TACs can be observed in static and dynamic PET analysis (c, d)
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and suspicion of tumor relapse should be taken into ac-
count in the further treatment rationale especially within
the first two years.
Eventhough TTPmin was significantly shorter in tumor
recurrences as compared to radiation-induced lesions,
no reliable cutoff could be established for this parameter
currently diminishing its prognostic impact. More data
are necessary to determine its place within the diagnos-
tic platform of brain metastases.
It should be stressed that not all patients had under-
gone stereotactic biopsy for histopathological verification
(this was considered unethical in patients with suspected
stable radiation-induced lesions). Systematic evaluation
of 18F-FET PET uptake patterns in untreated and already
irradiated tumors under consideration of the primary
tumor will certainly help to overcome data heterogeneity
and might be realized in the framework of future multi-
centre trials. The still increasing number of cancer pa-
tients will act as a pressure into this direction.
Conclusions
18F-FET PET appears to be an attractive tool in the dif-
ferentiation of tumor recurrences and radiation-induced le-
sions and its place is clearly beyond structural imaging.
The combination of static (TBRs) and dynamic (TACs) pa-
rameters shows high sensitivity, specificity and accuracy
values. Still, 18F-FET PET should be considered an addition
rather than a replacement of stereotactic biopsy and close
follow-up. This is especially true for selected ambiguous
cases to avoid overtreatment or undertreatment.
Abbreviations
11C-MET: L-Methyl-11C-Methionine; 18F-FDG: 18F-2-Deoxy-2-Fluoro-D-Glucose;
18F-FET PET: O-(2-18F-Fluoroethyl)-L-Tyrosine; BBB: Blood brain barrier;
CT: Computerized tomography; FLAIR: Fluid attenuated inversion recovery;
MRI: Magnetic resonance imaging; ROC: Receiver operating characteristic;
SBT: Stereotactic iodine-125 brachytherapy; SRS: Stereotactic radiosurgery;
SUV: Standardized uptake value; TAC: Time activity curve; TBRmax: Maximum
tumor-to-background ratio; TBRmean: Mean tumor-to-background ratio;




There were no funding sources for this study.
Availability of data and materials
The clinical dataset supporting the conclusions of this article is available in
the results section (Table 1).
Authors’ contributions
All authors contributed extensively to the work presented in this paper.
AR conceived the study, acquired and evaluated all data and prepared the
manuscript. MU and MB participated in the clinical and nuclear medicine
data collection and helped to draft the manuscript. CST was engaged in the
radiological data acquisition and evaluation. JCT and PB supervised and
commented the analysis on all stages and edited the manuscript. SBN and
AM contributed to collection of radiotherapeutic data and helped to draft
the Methods and Discussion part. FWK and NLA designed and supervised
the study and wrote the manuscript. All authors read and approved the
final manuscript.
Competing interests




In this retrospective study, ethical approval was waived by our institutional
review board.
Author details
1Department of Neurosurgery, Ludwig-Maximilians-University of Munich, Munich,
Germany. 2Department of Nuclear Medicine, Ludwig-Maximilians-University of
Munich, Marchioninistr. 15, 81377 Munich, Germany. 3Institute of Clinical
Radiology, Ludwig-Maximilians-University of Munich, Munich, Germany.
4Department of Radiation Oncology, Hospital of the University of Munich,
Campus Grosshadern, Ludwig-Maximilians-University of Munich, Munich,
Germany. 5European CyberKnife Center Munich, Munich, Germany.
Received: 19 June 2016 Accepted: 11 October 2016
References
1. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-
brain radiation therapy vs stereotactic radiosurgery alone for treatment of
brain metastases: a randomized controlled trial. JAMA. 2006;295:2483–91.
2. Schüttrumpf LH, Niyazi M, Nachbichler SB, et al. Prognostic factors for
survival and radiation necrosis after stereotactic radiosurgery alone or in
combination with whole brain radiation therapy for 1–3 cerebral
metastases. Radiat Oncol. 2014;9:105.
3. Ruge MI, Kickingereder P, Grau S, Hoevels M, Treuer H, Sturm V. Stereotactic
biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis
and treatment of locally recurrent single brain metastases. J Neurooncol.
2011;105:109–18.
4. Szeifert GT, Atteberry DS, Kondziolka D, Levivier M, Lunsford LD. Cerebral
metastases pathology after radiosurgery: a multicenter study. Cancer.
2006;106:2672–81.
5. Ross DA, Sandler HM, Balter JM, Hayman JA, Archer PG, Auer DL. Imaging
changes after stereotactic radiosurgery of primary and secondary malignant
brain tumors. J Neurooncol. 2002;56:175–81.
6. Jansen NL, Suchorska B, Schwarz SB, et al. [18F]fluoroethyltyrosine-positron
emission tomography-based therapy monitoring after stereotactic iodine-125
brachytherapy in patients with recurrent high-grade glioma. Mol Imaging.
2013;12:137–47.
7. Minniti G, Scaringi C, Paolini S, et al. Repeated stereotactic radiosurgery for
patients with progressive brain metastases. J Neurooncol. 2016;126:91–7.
8. Dooms GC, Hecht S, Brant-Zawadzki M, et al. Brain radiation lesions: MR
imaging. Radiology. 1986;158:149–55.
9. Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase
FDG-PET imaging of brain metastases provides superior assessment of
recurrence versus post-treatment necrosis. J Neurooncol. 2011;103:137–46.
10. Galldiks N, Stoffels G, Filss CP, et al. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine
PET for differentiation of local recurrent brain metastasis from radiation
necrosis. J Nucl Med. 2012;53:1367–74.
11. Tsuyuguchi N, Sunada I, Iwai Y, et al. Methionine positron emission
tomography of recurrent metastatic brain tumor and radiation necrosis after
stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg.
2003;98:1056–64.
12. Galldiks N, Langen KJ, Pope WB. From the clinician’s point of view - What is
the status quo of positron emission tomography in patients with brain
tumors? Neuro Oncol. 2015;17:1434–44.
13. Suchorska B, Jansen NL, Linn J, et al. Biological tumor volume in 18FET-PET
before radiochemotherapy correlates with survival in GBM. Neurology.
2015;847:710–9.
14. Suchorska B, Albert NL, Tonn JC. Usefulness of PET imaging to guide
treatment options in gliomas. Curr Treat Options Neurol. 2016;18:4.
15. Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of
O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine
(MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol
Biol Phys. 2011;81:1049–58.
Romagna et al. Radiation Oncology  (2016) 11:139 Page 9 of 10
16. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II
studies of malignant glioma. J Clin Oncol. 1990;8:1277–80.
17. Schwartz C, Romagna A, Thon N, et al. Outcome and toxicity profile of
salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent
high-grade gliomas. Acta Neurochir. 2015;157:1757–64.
18. Thon N, Eigenbrod S, Grasbon-Frodl EM, et al. Novel molecular stereotactic
biopsy procedures reveal intratumoral homogeneity of loss of
heterozygosity of 1p/19q and TP53 mutations in World Health Organization
grade II gliomas. J Neuropathol Exp Neurol. 2009;68:1219–28.
19. Jansen NL, Schwartz C, Graute V, et al. Prediction of oligodendroglial
histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in
intracranial WHO grade II and III gliomas. Neuro Oncol. 2012;14:1473–80.
20. Jansen NL, Suchorska B, Wenter V, et al. Prognostic significance of dynamic
18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med.
2015;56:9–15.
21. Thon N, Kunz M, Lemke L, et al. Dynamic 18F-FET PET in suspected WHO
grade II gliomas defines distinct biological subgroups with different clinical
courses. Int J Cancer. 2015;136:2132–45.
22. Lizarraga KJ, Allen-Auerbach M, Czernin J, et al. (18)F-FDOPA PET for
differentiating recurrent or progressive brain metastatic tumors from late or
delayed radiation injury after radiation treatment. J Nucl Med. 2014;55:30–6.
23. Cicone F, Minniti G, Romano A, et al. Accuracy of F-DOPA PET and
perfusion-MRI for differentiating radionecrotic from progressive brain
metastases after radiosurgery. Eur J Nucl Med Mol Imaging. 2015;42:103–11.
24. Filss C, Jansen N, Böning G, et al. Methodenvergleich der FET PET von
Hirntumoren in zwei großen Zentren. Hannover: Kongress der Deutschen
Gesellschaft für Nuklearmedizin; 2015. p. 53. Conference paper, abstract nr. V36.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Romagna et al. Radiation Oncology  (2016) 11:139 Page 10 of 10
